deltatrials
Completed NA INTERVENTIONAL 2-arm NCT05555030

COVID-19 iCura SARS-CoV-2 Ag OTC: Clinical Evaluation

iCura Diagnostics, LLC / COVID-19 Antigen Rapid Home Test Over the Counter Rapid Antigen Self-Test for Detection of SARS-CoV-2 Virus: Clinical Evaluation

Sponsor: New Day Diagnostics

Conditions COVID-19 SARS-CoV-2 Infection
Interventions RT-PCR Test iCura COVID-19 Antigen Rapid Home Test
Updated 5 times since 2022 Last updated: Feb 13, 2023 Started: Aug 4, 2022 Primary completion: Dec 20, 2022 Completion: Dec 20, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05555030, this NA trial focuses on COVID-19 and SARS-CoV-2 Infection and remains completed. Sponsored by New Day Diagnostics, it has been updated 5 times since 2022, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

~Sep 2022 – ~Mar 2023 · 6 months · monthly snapshotRecruiting~Mar 2023 – ~Dec 2023 · 9 months · monthly snapshotCompleted~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed NA

  2. Jul 2024 — Sep 2024 [monthly]

    Completed NA

  3. Dec 2023 — Jul 2024 [monthly]

    Completed NA

  4. Mar 2023 — Dec 2023 [monthly]

    Completed NA

    Status: Recruiting → Completed

  5. Sep 2022 — Mar 2023 [monthly]

    Recruiting NA

    First recorded

Aug 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • New Day Diagnostics
  • Paragon Rx Clinical, Inc.
  • iCura Diagnostics, LLC
Data source: New Day Diagnostics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations